OBIO Orchestra BioMed Holdings, Inc.: institutional ownership and insider trading
85 funds reported holding $128M of Orchestra BioMed Holdings, Inc. in their latest 13F filings; in Q2 2026 funds net bought $20.0M, with 25 new positions and 13 funds selling out; over the last 12 months insiders bought $280K and sold $353K on the open market; over its last four quarters it reported revenue of $32.0M and net income of −$59.0M.
OBIO revenue and earnings
- Quarter ended Jun 30, 2026: revenue $88.0K, net income −$23.8M, EPS -0.38
- Quarter ended Mar 31, 2026: revenue $110K, net income −$20.7M, EPS -0.33
- Quarter ended Dec 31, 2025: revenue $30.9M, net income $6.25M, EPS 0.28
- Quarter ended Sep 30, 2025: revenue $861K, net income −$20.8M, EPS -0.40
Famous investors holding OBIO
- Renaissance Technologies (Renaissance Technologies): $388K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $371K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $97.4K, 0.0% of the portfolio
Largest institutional holders of OBIO
- RTW INVESTMENTS, LP — $41.2M
- PERCEPTIVE ADVISORS LLC — $21.7M
- BlackRock, Inc. (BLK) — $10.8M
- VANGUARD CAPITAL MANAGEMENT LLC — $8.73M
- VANGUARD GROUP INC — $6.66M
- GEODE CAPITAL MANAGEMENT, LLC — $4.35M
- Alyeska Investment Group, L.P. — $4.32M
- Propel Bio Management, LLC — $3.87M
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC — $2.77M
- STATE STREET CORP (STT, STT-PG) — $2.23M
Recent OBIO insider trades
- Oct 1, 2026: Sherman Darren sold 15,000 shares ($95.4K)
- Sep 3, 2026: Hochman David P bought 10,000 shares ($47.9K)
- Sep 1, 2026: Sherman Darren sold 15,000 shares ($74.1K)
- Aug 26, 2026: Sherman Darren bought 2,000 shares ($10.7K)
5%+ owners
- RTW Investments, LP: 19.2% (Schedule 13D/A, filed Apr 29, 2026)